Each case demonstrates a different facet of the Ashebo Method's druggability analysis. Together, they prove the platform can deliver three distinct outcomes:
"Yes, but carefully" — β-catenin shows recurring 299–312 Da hypotheses across five conformational states, suggesting structural tractability despite decades of failed drug programs.
"No, clearly" — MYC (12/100) and α-synuclein (0/100) are correctly identified as undruggable by conventional small molecules, consistent with decades of failed programs.
"This domain, not that one" — TDP-43 RRM1 is the strongest small-molecule region while other domains are weaker; p53 Y220C recovers the clinically validated rescued pocket at 93/100 with a 338 Da lead matching rezatapopt (~360 Da).